Hundreds of organizational validations Pathological grade IHC antibody

1. The difference between ImmunoWay pathological grade antibodies and ordinary antibodies

The investment in research and development, from the design of immunogens to the screening and validation of antibodies, far exceeds that of scientific research on antibodies; The design of immunogens is targeted towards peptides used in IHC applications, with much better specificity. The screening of clones and the validation of antibodies are all tested through thousands of positive and negative tissue sections, which is very strict;

2. Screening criteria for pathological antibodies

The specificity of antibodies is strong, with low background, and more importantly, the contrast between positive and negative is very high

3.ImmunoWay Pathological Grade IHC Application Antibody Catalog